476 related articles for article (PubMed ID: 11937555)
1. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
2. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
3. A stable single-chain variable fragment expressing transfectoma demonstrates induction of idiotype-specific cytotoxic T-cells during early growth stages of a murine B-lymphoma.
Laxmanan S; Stuart GW; Ghosh SK
Cancer Immunol Immunother; 2001 Oct; 50(8):437-44. PubMed ID: 11726138
[TBL] [Abstract][Full Text] [Related]
4. Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.
Warncke M; Buchner M; Thaller G; Dodero A; Bulashevska A; Pfeifer D; Timmer J; Veelken H
Cancer Immunol Immunother; 2011 Jan; 60(1):49-60. PubMed ID: 20848095
[TBL] [Abstract][Full Text] [Related]
5. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.
Schirmbeck R; Reimann J; Kochanek S; Kreppel F
Mol Ther; 2008 Sep; 16(9):1609-16. PubMed ID: 18612271
[TBL] [Abstract][Full Text] [Related]
6. Immunodominance of Adenovirus-Derived CD8
Schöne D; Hrycak CP; Windmann S; Lapuente D; Dittmer U; Tenbusch M; Bayer W
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768877
[TBL] [Abstract][Full Text] [Related]
7. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.
Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S
Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
9. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
10. Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants.
Benvenuti F; Burrone OR
Gene Ther; 2001 Oct; 8(20):1555-61. PubMed ID: 11704816
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterial HSP70 as an adjuvant in the design of an idiotype vaccine against a murine lymphoma.
Karyampudi L; Ghosh SK
Cell Immunol; 2008; 254(1):74-80. PubMed ID: 18715553
[TBL] [Abstract][Full Text] [Related]
13. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
14. [Construction and expression of a prokaryotic expression plasmid of idiotypic vaccine against B cell lymphoma: encoding the fusion genes of single-chain variable fragment and MCP-3].
Wang FX; Zhao B; Cheng YH; Pan L; Luo JM; Zhang XJ; Dong ZR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1151-5. PubMed ID: 17204183
[TBL] [Abstract][Full Text] [Related]
15. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.
Kanter G; Yang J; Voloshin A; Levy S; Swartz JR; Levy R
Blood; 2007 Apr; 109(8):3393-9. PubMed ID: 17164345
[TBL] [Abstract][Full Text] [Related]
16. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
17. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
Cesco-Gaspere M; Benvenuti F; Burrone OR
Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
[TBL] [Abstract][Full Text] [Related]
18. Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype.
Sparer TE; Wynn SG; Clark DJ; Kaplan JM; Cardoza LM; Wadsworth SC; Smith AE; Gooding LR
J Virol; 1997 Mar; 71(3):2277-84. PubMed ID: 9032363
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.
Syrengelas AD; Levy R
J Immunol; 1999 Apr; 162(8):4790-5. PubMed ID: 10202021
[TBL] [Abstract][Full Text] [Related]
20. Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine.
Lim SY; Laxmanan S; Stuart G; Ghosh SK
Cancer Detect Prev; 2001; 25(5):470-8. PubMed ID: 11718453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
